Ashvattha Therapeutics to Present Preclinical Data at the CMSC and SNMMI Annual Meetings
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that the company will present preclinical data at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) and Society of Nuclear Medicine & Molecular Imaging 2024 annual meetings.
- REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that the company will present preclinical data at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) and Society of Nuclear Medicine & Molecular Imaging 2024 annual meetings.
- The presentations will demonstrate the therapeutic potential of Ashvattha’s novel CSF1R dendranib for MS, based on symptom reduction in a mouse experimental autoimmune encephalitis (EAE) model of MS. Additionally, the presentation by Ashvattha’s collaborators at Stanford University will demonstrate reduction in neuroinflammation following CSF1R dendranib treatment by PET imaging using Ashvattha’s proprietary 18F-OP-801 radioimaging agent.
- Details for the presentations are as follows:
May 29 – June 1, 2024